Semarang – Besides the Red and White vaccine, it turns out that currently there is a COVID-19 vaccine made by the nation’s children, namely the Nusantara vaccine. The stage is now entering phase II clinical trials.
The vaccine uses Dendritic cell technology in which one vaccine is made for only one person so it is called safe for people who have comorbids. The former Minister of Health, Terawan Agus Putranto who is also the initiator of the production of the Nusantara vaccine today saw the preparation for phase II clinical trials at dr. Kariadi Semarang.
Terawan said the collaboration between PT. Rama Emerald Multi Sukses (Rama Pharma) with AIVITA Biomedical from the United States, Diponegoro University (Undip), and dr. Kariadi Semarang conducts development and clinical trials of Nusantara Vaccines.
“The clinical trial I was completed with good results, good immunity and safety results. Right clinical trials I control the safety of the patient. Of the 30 patients, the immunogenicity was good, “he explained.
Described, the vaccine comes from autologous dendritic cells (components of white blood cells) exposed to the protein S antigen from SARS-COV-2. Dendritic cells that have recognized the antigen will be injected back into the body. In the body, these dendritic cells will trigger other immune cells to form a memory defense system against SARS COV-2.
“Cell dendritic based vaccines. Being introduced to the COVID-19 antigen so you have a memory of COVID-19. The simple process is incubation a week later into individual vaccines and injections, “he said.
According to Terawan, the concept of general vaccination is changed personally quite important because the comorbid conditions of each individual are different. However, he can ensure that mass production can still be carried out even though it is individual.
“So people think they can’t produce mass products. It could even be 10 million a month, it could be done, “he said.
Various processes have been passed in the development of the vaccine, including starting October 12, 2020, namely the establishment of the Dendritic Cell Vaccine Research Team by the Ministry of Health KMK No. HK.01.07 / MENKES / 2646/2020.
